Salarius Pharmaceuticals Files S-1 for Potential Stock Offering

Ticker: DCOY · Form: S-1 · Filed: Jan 21, 2025 · CIK: 1615219

Salarius Pharmaceuticals, INC. S-1 Filing Summary
FieldDetail
CompanySalarius Pharmaceuticals, INC. (DCOY)
Form TypeS-1
Filed DateJan 21, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $2.69
Sentimentneutral

Sentiment: neutral

Topics: s-1, filing, pharmaceuticals, capital-raise

TL;DR

Salarius Pharma (FLKS) filing S-1, looks like they're raising cash.

AI Summary

Salarius Pharmaceuticals, Inc. filed an S-1 form on January 21, 2025, indicating a potential offering of securities. The company, formerly known as Flex Pharma, Inc. until July 30, 2014, is based in Houston, Texas. This filing suggests the company is preparing to raise capital through the sale of stock.

Why It Matters

This S-1 filing signals Salarius Pharmaceuticals' intent to access public markets for funding, which could fuel its research and development or expansion efforts.

Risk Assessment

Risk Level: medium — S-1 filings indicate a company is seeking capital, which can be a positive sign but also carries inherent risks associated with public offerings and the company's specific financial health and market position.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this S-1 filing for Salarius Pharmaceuticals, Inc.?

The S-1 filing indicates that Salarius Pharmaceuticals, Inc. is preparing to offer its securities to the public, likely to raise capital for its business operations.

When was the S-1 filing submitted to the SEC?

The S-1 filing was submitted to the SEC on January 21, 2025.

What was Salarius Pharmaceuticals, Inc. previously known as?

Salarius Pharmaceuticals, Inc. was formerly known as Flex Pharma, Inc., with the name change occurring on July 30, 2014.

Where is Salarius Pharmaceuticals, Inc. located?

Salarius Pharmaceuticals, Inc. is located in Houston, Texas.

What is the SIC code associated with Salarius Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Salarius Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,478 words · 18 min read · ~15 pages · Grade level 19.1 · Accepted 2025-01-21 08:01:18

Key Financial Figures

Filing Documents

Use of Proceeds

Use of Proceeds 62 Market Price Information 63 Dividend Policy 64 Capitalization 65

Dilution

Dilution 67 Salarius' Business 69 Decoy's Business 79

Management's Discussion and Analysis of Financial Condition and Results of Operations of Salarius

Management's Discussion and Analysis of Financial Condition and Results of Operations of Salarius 133

Management's Discussion and Analysis of Financial Condition and Results of Operations of Decoy

Management's Discussion and Analysis of Financial Condition and Results of Operations of Decoy 141 Salarius Management 147 Decoy Management 152 Management Following the Merger 153 Salarius Executive Compensation 155 Decoy Executive Compensation 163 Principal Stockholders of Salarius 165 Principal Stockholders of the Combined Company 167 Certain Relationship and Related Party Transactions of Salarius 169 Certain Relationships and Related Party Transactions of Decoy 171

Description of Capital Stock

Description of Capital Stock 172

Description of Securities Salarius is Offering

Description of Securities Salarius is Offering 176 Material U.S Federal Income Tax Consequences 179

Underwriting

Underwriting 185 Legal Matters 189 Experts 189 Where You Can Find More Information 189 Unaudited Pro Forma Consolidated Combined Financial Information 190 Index to Financial Statements F- i References to " Salarius " and " Decoy " in this prospectus refer to Salarius Pharmaceuticals, Inc. and Decoy Therapeutics, Inc., respectively. References to the " combined company " refer to Salarius and its wholly owned subsidiary, Decoy, after the Merger, assuming the Merger is consummated. Except as otherwise noted, references to " we ," " us " or " our " refer to Salarius. References to " First Merger Sub " refer to Decoy Therapeutics MergerSub I, Inc., a newly formed, wholly owned subsidiary of Salarius and references to " Second Merger Sub " refer to Decoy Therapeutics MergerSub II, LLC, a newly formed, wholly owned subsidiary of Salarius. References to the " Merger Agreement " refer to that certain Agreement and Plan of Merger dated as of January 10, 2025, among Salarius, First Merger Sub, Second Merger Sub and Decoy, as amended from time to time. References to the " Merger " refers collectively to the merger of First Merger Sub with and into Decoy, with Decoy surviving as the surviving entity and as a wholly owned subsidiary of Salarius, and the merger of Decoy with and into Second Merger Sub, with Second Merger Sub being the surviving entity and continuing under the name "Decoy Therapeutics, LLC" as a wholly owned subsidiary of Salarius, in each case as contemplated under the Merger Agreement. ABOUT THIS PROSPECTUS Neither Salarius nor the underwriters have authorized anyone to provide any information other than that contained in this prospectus or in any free writing prospectus that Salarius has authorized for use in connection with this offering. Salarius takes no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell, or a

Forward-looking statements in this prospectus include, but are not limited to, statements about the following

Forward-looking statements in this prospectus include, but are not limited to, statements about the following: the expected benefits of, and potential value created by, the Merger for the securityholders of Salarius and Decoy; the likelihood of the satisfaction of certain conditions to the completion of the Merger, including the conditions related to this offering, whether and when the Merger will be consummated and that Salarius' common stock remains listed on Nasdaq; the expected amount of Salarius' cash amount to be delivered at the closing of the Merger and Salarius' ability to control and correctly estimate its operating expenses and its expenses associated with the Merger, including potential litigation expenses; the effects of the Merger and this offering on the ownership percentages of the Decoy's stockholders and Salarius' stockholders in the combined company; the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings, commencement of preclinical studies or clinical trials and release of data from such studies or trials; plans to develop and commercialize additional products candidates including planned preclinical, clinical, regulatory, commercialization and manufacturing activities; the attraction and retention of highly qualified personnel; the ability to protect and enhance the combined company's products and intellectual property; developments and projections relating to the combined company's competitors or industry; the combined company's financial performance; Salarius' or Decoy's relationships and actions with third parties; Salarius' and the combined company's ability to maintain the listing of its shares of common stock on Nasdaq, and the potential liquidity and trading of such shares of common stock; the ability of Salarius and the combined company to successfully manage its cash and cash equivalents and any anticipated proceeds from th

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing